Us Bancorp \De\ Eye Point Pharmaceuticals, Inc. Transaction History
Us Bancorp \De\
- $82.9 Billion
- Q3 2025
A detailed history of Us Bancorp \De\ transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 29 shares of EYPT stock, worth $343. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29
Previous 29
-0.0%
Holding current value
$343
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding EYPT
# of Institutions
167Shares Held
68MCall Options Held
421KPut Options Held
401K-
Cormorant Asset Management, LP Boston, MA8.33MShares$98.7 Million18.35% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.19MShares$73.4 Million2.57% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.56MShares$65.9 Million0.13% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.42MShares$52.3 Million0.12% of portfolio
-
Franklin Resources Inc San Mateo, CA4.17MShares$49.4 Million0.02% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $404M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...